ReviewReumatologia2018
Psoriasis in special localizations.
Review in Reumatologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Efficacy and Safety of Oral Icotrokinra in Moderate-to-Severe Plaque Psoriasis: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.International journal of dermatology · 2026Pooled it
- A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.Inflammopharmacology · 2026Pooled it
- Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Clinical drug investigation · 2024Pooled it
- Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in psoriasis: a systematic review and meta-analysis.Archives of dermatological research · 2024Pooled it
- Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2022Pooled it
- Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.American journal of clinical dermatology · 2025Trial
- Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study.Dermatology and therapy · 2026Article
- Prevalence of Genital Psoriasis and Its Impact on Patients' Sexual Life in Routine Care: Epidemiologic Survey in Germany.Psoriasis (Auckland, N.Z.) · 2026Article
- Ocular complications in psoriasis and psoriatic arthritis.Reumatologia · 2026Review
- Epidemiology and clinical features of psoriasis in hard-to-treat body locations: a Chinese nationwide population-based study.BMC immunology · 2025Observational
- A Transcriptomic Atlas of Healthy Human Skin Links Regional Identity to Inflammatory Disease.bioRxiv : the preprint server for biology · 2025Article
- Hard-to-Treat Areas in Psoriasis: An Underevaluated Part of the Disease.Life (Basel, Switzerland) · 2025Review
- Update vulval dermatology - diagnostics and therapy.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- Updates on Psoriasis in Special Areas.Journal of clinical medicine · 2024Review
- Is there still a place for neutrophil gelatinase-associated lipocalin to serve as a biomarker in psoriasis?Postepy dermatologii i alergologii · 2024Article
- Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.Dermatology and therapy · 2024Article
- Psoriasis localization patterns in the Swiss Psoriasis Registry (SDNTT) over 11 years: an analysis by sex and age.Archives of dermatological research · 2024Article
- Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States.Dermatology and therapy · 2024Article
- CD1a and skin T cells: a pathway for therapeutic intervention.Clinical and experimental dermatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory dermatosis affecting 1-3% of the general population. Patients with psoriasis represent a heterogeneous population with individual disease expression - different degrees and severity of skin involvement. Psoriatic lesions in particular localizations such as the face, scalp, intertriginous or palmoplantar areas significantly reduce quality of life. Patients often feel ashamed, embarrassed, or self-conscious about their symptoms. Furthermore, genital psoriasis significantly affects sexual health. Among patients with psoriasis, the prevalence of special localizations is estimated to be 23-27% on the nails, 49% on the face, 12-16% on the palms and soles, and up to 36% in intertriginous regions. Due to peculiar features of skin in these areas, adequate and specific management is required, which is discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.